Advertisement

Ibopamine

  • Adam Schneeweiss
  • Gotthard Schettler
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 72)

Abstract

Ibopamine is a dopaminergic agonist recently shown to reduce renal arterial resistance and increase myocardial contractility and diuresis, without affecting heart rate or blood pressure in healthy volunteers, in patients with congestive heart failure, or in animals [1–5]. In patients with congestive heart failure, ibopamine significantly increased cardiac index and stroke work index, and decreased pulmonary pressure and pulmonary and peripheral vascular resistance without affecting heart rate or blood pressure. These effects were observed also in elderly patients. For example, in a 79-year-old patient with ischemic cardiomyopathy and chronic congestive heart failure (functional class 3), ibopamine increased cardiac index from 2.99 to 4.07 L/min·m2 (36%) and decreased systemic vascular resistance from 1748 to 1237 dyn·sec·cm-5 (29%) and pulmonary capillary wedge pressure from 17 to 14 mmHg (18%). In a 73-year-old patient with ischemic cardiomyopathy and congestive heart failure (functional class 4), ibopamine increased cardiac index from 2.85 to 5.04 L/min·m2 (77%) and decreased systemic vascular resistance from 1736 to 891 dyn·sec·cm-5. Pulmonary capillary wedge pressure was not significantly altered [6].

Keywords

Congestive Heart Failure Cardiac Index Functional Class Systemic Vascular Resistance Pulmonary Capillary Wedge Pressure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Dei Cas L, et al: Non-invasive evaluation of the effects of oral biopamine (SB 7505) on cardiac and renal function in patients with congestive heart failure. J Cardiovasc Pharmacol 4:436, 1982.PubMedCrossRefGoogle Scholar
  2. 2.
    Ladelli L, et al: Acute effects of ibopamine on cardiac performance: an echocardiographic and polygraphic study. G Ital Cardiol 13:239, 1983.PubMedGoogle Scholar
  3. 3.
    Dei Cas L, et al: Hemodynamic effects of ibopamine in patients with idiopathic congestive cardiomyopathy. J Cardiovasc Pharmacol 5:249, 1983.PubMedCrossRefGoogle Scholar
  4. 4.
    Mengeot PH, et al: Double-blind hemodynamic study of a new dopamine derivative (diisobutyric ester of N-methyl-dopamine) orally active in chronic congestive heart failure. G Ital Cardiol 40:900, 1977.Google Scholar
  5. 5.
    Ren JH, et al: The dopamine congener, ibopamine, in congestive heart failure. J Cardiovasc Pharmacol 6:748, 1984.CrossRefGoogle Scholar
  6. 6.
    Marchionni N, et al: Ibopamine in congestive heart failure refractory in digitalis, diuretics and Captopril. Clin Pharmacol (in press).Google Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1988

Authors and Affiliations

  • Adam Schneeweiss
    • 1
  • Gotthard Schettler
    • 2
  1. 1.Geriatric Cardiology Research FoundationTel-AvivIsrael
  2. 2.Department of MedicineUniversity of HeidelbergGermany

Personalised recommendations